{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:22:06Z","timestamp":1789590126673,"version":"build-2803163510"},"reference-count":84,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Antipsychotics interfere with virtually all hallmarks of cancer, including angiogenesis.\nVascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth receptors\n(PDGFRs) play crucial roles in angiogenesis and represent targets of many anti-cancer agents.\nWe assessed and compared the binding effects of antipsychotics and receptor tyrosine kinase inhibitors\n(RTKIs) on VEGFR2 and PDGFR\u03b1.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>FDA-approved antipsychotics and RTKIs were retrieved from DrugBank. VEGFR2 and\nPDGFR\u03b1 structures were obtained from Protein Data Bank and loaded on Biovia Discovery Studio\nsoftware to remove nonstandard molecules. Molecular docking was carried out using PyRx and CBDock\nto determine the binding affinities of protein-ligand complexes.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Risperidone exerted the highest binding effect on PDGFR\u03b1 (-11.0 Kcal\/mol) as compared to\nother antipsychotic drugs and RTKIs. Risperidone also demonstrated a stronger binding effect on\nVEGFR2 (-9.6 Kcal\/mol) than the RTKIs, pazopanib (-8.7 Kcal\/mol), axitinib (-9.3 Kcal\/mol),\nvandetanib (-8.3 Kcal\/mol), lenvatinib ( -7.6 Kcal\/mol) and sunitinib (-8.3 Kcal\/mol). Sorafenib (an\nRTKI), however, exhibited the highest VEGFR2 binding affinity of -11.7 Kcal\/mol.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Risperidone's superior binding affinity with PDGFR\u03b1 when compared to all reference\nRTKIs and antipsychotic drugs, as well as its stronger binding effect on VEGFR2 over the RTKIs,\nsunitinib, pazopanib, axitinib, vandetanib, and lenvatinib, imply that it could be repurposed to inhibit\nangiogenic pathways and subjected to pre-clinical and clinical trials for cancer therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570163820666230606113158","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T07:37:37Z","timestamp":1686123457000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Repurposing Antipsychotic Agents Against Targets of Angiogenesis\nPathways for Cancer Therapy: An in-silico Approach"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4906-4067","authenticated-orcid":true,"given":"Rahmon","family":"Kanmodi","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Faculty of Science, Lagos State University, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habeeb","family":"Bankole","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Science, Lagos State University, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Oddiri","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Science, Lagos State University, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Arowosegbe","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\nand Toxicology, University of Arizona, Tucson, Arizona, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridwan","family":"Alabi","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry,\nEko University of Medicine and Health Sciences, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saheed","family":"Rahmon","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Science, Lagos State University, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladejo","family":"Ahmodu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Science, Lagos State University, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"AbdulRasheed","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Science, Lagos State University, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rauf","family":"Muritala","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Science, Lagos State University, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1017\/S0033291719003957","volume":"51","author":"Siafis S.","year":"2021","unstructured":"Siafis S.; Davis J.M.; Leucht S.; Antipsychotic drugs: From \u2018major tranquilizers\u2019 to neuroscience-based-nomenclature. Psychol Med 2021,51(3),522-524","journal-title":"Psychol Med"},{"key":"ref=2","first-page":"5234","volume":"10","author":"Bari D.","year":"2019","unstructured":"Bari D.; Saravanan K.; Ahmad A.; A review on antipsychotics for schizophrenia. Int J Pharm Sci Res 2019,10(12),5234-5251","journal-title":"Int J Pharm Sci Res"},{"key":"ref=3","first-page":"116","volume":"2","author":"Nerkar A.","year":"2020","unstructured":"Nerkar A.; Bhise S.; Polypharmacological drugs in treatment of schizophrenia. Curr Trends Pharm Pharm Chem 2020,2(3),116-124","journal-title":"Curr Trends Pharm Pharm Chem"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jamda.2020.05.039","volume":"21","author":"Gerlach L.","year":"2020","unstructured":"Gerlach L.; Kales H.C.; Kim H.M.; Trends in antipsychotic and mood stabilizer prescribing in long-term care in the US: 2011\u20132014. J Am Med Dir Assoc 2020,21(11),1629-1635","journal-title":"J Am Med Dir Assoc"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.pnpbp.2018.01.023","volume":"84","author":"Olten B","year":"2018","unstructured":"Olten B; Bloch MH; Meta regression: Relationship between antipsychotic receptor binding profiles and side-effects. Prog Neuropsychopharmacol Biol Psychiatry 2018,84(Pt A),272-81","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=6","first-page":"140","volume":"43","author":"Bravo-Jos\u00e9 P.","year":"2019","unstructured":"Bravo-Jos\u00e9 P.; S\u00e1ez-Lle\u00f3 C.I.; Peris-Mart\u00ed J.F.; Deprescribing antipsychotics in long term care patients with dementia. Farm Hosp 2019,43(4),140-145","journal-title":"Farm Hosp"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/mp.2015.229","volume":"21","author":"Loryan I.","year":"2016","unstructured":"Loryan I.; Melander E.; Svensson M.; In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: Link to spatial receptor occupancy. Mol Psychiatry 2016,21(11),1527-1536","journal-title":"Mol Psychiatry"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/cells11020263","volume":"11","author":"Persico M.","year":"2022","unstructured":"Persico M.; Abbruzzese C.; Matteoni S.; Tackling the behavior of cancer cells: Molecular bases for repurposing antipsychotic drugs in the treatment of glioblastoma. Cells 2022,11(2),263","journal-title":"Cells"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"105136","DOI":"10.1016\/j.nbd.2020.105136","volume":"146","author":"Blokhin I.O.","year":"2020","unstructured":"Blokhin I.O.; Khorkova O.; Saveanu R.V.; Wahlestedt C.; Molecular mechanisms of psychiatric diseases. Neurobiol Dis 2020,146(105136),105136","journal-title":"Neurobiol Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3390\/molecules23082087","volume":"23","author":"St\u0119pnicki P.","year":"2018","unstructured":"St\u0119pnicki P.; Kondej M.; Kaczor A.A.; Current concepts and treatments of schizophrenia. Molecules 2018,23(8),2087","journal-title":"Molecules"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e013881","DOI":"10.1136\/bmjopen-2016-013881","volume":"7","author":"Keating D.","year":"2017","unstructured":"Keating D.; McWilliams S.; Schneider I.; Pharmacological guidelines for schizophrenia: A systematic review and comparison of recommendations for the first episode. BMJ Open 2017,7(1),e013881","journal-title":"BMJ Open"},{"key":"ref=12","first-page":"638","volume":"39","author":"Patel K.R.","year":"2014","unstructured":"Patel K.R.; Cherian J.; Gohil K.; Atkinson D.; Schizophrenia: Overview and treatment options. PandT 2014,39(9),638-645","journal-title":"PandT"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"Leucht S.","year":"2013","unstructured":"Leucht S.; Cipriani A.; Spineli L.; Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 2013,382(9896),951-962","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"Leucht S.","year":"2009","unstructured":"Leucht S.; Corves C.; Arbter D.; Engel R.R.; Li C.; Davis J.M.; Second-generation vs. first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009,373(9657),31-41","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1192\/bjp.bp.109.066217","volume":"196","author":"Crossley N.A.","year":"2010","unstructured":"Crossley N.A.; Constante M.; McGuire P.; Power P.; Efficacy of atypical vs. typical antipsychotics in the treatment of early psychosis: Meta-analysis. Br J Psychiatry 2010,196(6),434-439","journal-title":"Br J Psychiatry"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","volume":"9","author":"Mattiuzzi C.","year":"2019","unstructured":"Mattiuzzi C.; Lippi G.; Current cancer epidemiology. J Epidemiol Glob Health 2019,9(4),217-222","journal-title":"J Epidemiol Glob Health"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"605680","DOI":"10.3389\/fonc.2020.605680","volume":"10","author":"Hern\u00e1ndez-Lemus E.","year":"2021","unstructured":"Hern\u00e1ndez-Lemus E.; Mart\u00ednez-Garc\u00eda M.; Pathway-based drug-repurposing schemes in cancer: The role of translational bioinformatics. Front Oncol 2021,10(605680),605680","journal-title":"Front Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"72322","DOI":"10.18632\/oncotarget.11875","volume":"7","author":"Rybinski B.","year":"2016","unstructured":"Rybinski B.; Yun K.; Addressing intra-tumoral heterogeneity and therapy resistance. Oncotarget 2016,7(44),72322-72342","journal-title":"Oncotarget"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fcell.2018.00056","volume":"6","author":"Comen E.A.","year":"2018","unstructured":"Comen E.A.; Bowman R.L.; Kleppe M.; Underlying causes and therapeutic targeting of the inflammatory tumor microenvironment. Front Cell Dev Biol 2018,6(56),56","journal-title":"Front Cell Dev Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.3390\/cancers14153743","volume":"14","author":"Hersh A.M.","year":"2022","unstructured":"Hersh A.M.; Gaitsch H.; Alomari S.; Lubelski D.; Tyler B.M.; Molecular pathways and genomic landscape of glioblastoma stem cells: Opportunities for targeted therapy. Cancers 2022,14(15),3743","journal-title":"Cancers"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(72)92955-8","volume":"2","author":"Csatary L.","year":"1972","unstructured":"Csatary L.; Cancer and chlorpromazine. Lancet 1972,2,338-339","journal-title":"Lancet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/cncr.21574","volume":"104","author":"Barak Y.","year":"2005","unstructured":"Barak Y.; Achiron A.; Mandel M.; Mirecki I.; Aizenberg D.; Reduced cancer incidence among patients with schizophrenia. Cancer 2005,104(12),2817-2821","journal-title":"Cancer"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1192\/bjp.187.4.334","volume":"187","author":"Goldacre M.J.","year":"2005","unstructured":"Goldacre M.J.; Kurina L.M.; Wotton C.J.; Yeates D.; Seagroatt V.; Schizophrenia and cancer: An epidemiological study. Br J Psychiatry 2005,187(4),334-338","journal-title":"Br J Psychiatry"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccell.2015.08.012","volume":"28","author":"Shchors K.","year":"2015","unstructured":"Shchors K.; Massaras A.; Hanahan D.; Dual targeting of the autophagic regulatory circuitry in gliomas with repurposed drugs elicits cell-lethal autophagy and therapeutic benefit. Cancer Cell 2015,28(4),456-471","journal-title":"Cancer Cell"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/1758834016659791","volume":"8","author":"Faraz S.","year":"2016","unstructured":"Faraz S.; Pannullo S.; Rosenblum M.; Smith A.; Wernicke A.G.; Long-term survival in a patient with glioblastoma on antipsychotic therapy for schizophrenia: A case report and literature review. Ther Adv Med Oncol 2016,8(6),421-428","journal-title":"Ther Adv Med Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.neo.2017.10.002","volume":"20","author":"Kline C.L.B.","year":"2018","unstructured":"Kline C.L.B.; Ralff M.D.; Lulla A.R.; Role of dopamine receptors in the anticancer activity of ONC201. Neoplasia 2018,20(1),80-91","journal-title":"Neoplasia"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/biomedicines9121785","volume":"9","author":"Vlachos N.","year":"2021","unstructured":"Vlachos N.; Lampros M.; Voulgaris S.; Alexiou G.A.; Repurposing antipsychotics for cancer treatment. Biomedicines 2021,9(12),1785","journal-title":"Biomedicines"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1053\/j.gastro.2016.08.040","volume":"151","author":"Jandaghi P.","year":"2016","unstructured":"Jandaghi P.; Najafabadi H.S.; Bauer A.S.; Expression of DRD2 is increased in human pancreatic ductal adenocarcinoma and inhibitors slow tumor growth in mice. Gastroenterology 2016,151(6),1218-1231","journal-title":"Gastroenterology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","volume":"149","author":"Sachlos E.","year":"2012","unstructured":"Sachlos E.; Risue\u00f1o R.M.; Laronde S.; Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012,149(6),1284-1297","journal-title":"Cell"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.47176\/mjiri.34.99","volume":"34","author":"Olfati Z.","year":"2020","unstructured":"Olfati Z.; Rigi G.; Vaseghi H.; Zahra Z.; Sohrabi M.; Hejazi S.H.; Evaluation of serotonin receptors (5HTR2A and 5HTR3A) mRNA expression changes in tumor of breast cancer patients. Med J Islam Repub Iran 2020,34(99),99","journal-title":"Med J Islam Repub Iran"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/1573394714666180626155751","volume":"15","author":"Razavi S.A.","year":"2019","unstructured":"Razavi S.A.; Rahimi B.; Gholipour N.; Ahangari F.; Ahangari G.; Serotonin (5HTR2A and 5HTR3A) and GABA (GABAB) receptor genes overexpression are correlated with non-small cell lung cancer (NSCLC). Curr Cancer Ther Rev 2019,15(2),155-161","journal-title":"Curr Cancer Ther Rev"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2174\/1570163813666151126215210","volume":"12","author":"Hejazi S.","year":"2016","unstructured":"Hejazi S.; Ahangari G.; Deezagi A.; Alternative viewpoint against breast cancer based on selective serotonin receptors 5HTR3A and 5HTR2A antagonists that can mediate apoptosis in MCF-7 cell line. Curr Drug Discov Technol 2016,12(4),240-249","journal-title":"Curr Drug Discov Technol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2018.00248","volume":"8","author":"Zuazo-Gaztelu I.","year":"2018","unstructured":"Zuazo-Gaztelu I.; Casanovas O.; Unraveling the role of angiogenesis in cancer ecosystems. Front Oncol 2018,8,248","journal-title":"Front Oncol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"Hanahan D.","year":"2011","unstructured":"Hanahan D.; Weinberg R.A.; Hallmarks of cancer: The next generation. Cell 2011,144(5),646-674","journal-title":"Cell"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/biomedicines5020034","volume":"5","author":"Rajabi M.","year":"2017","unstructured":"Rajabi M.; Mousa S.; The role of angiogenesis in cancer treatment. Biomedicines 2017,5(4),34","journal-title":"Biomedicines"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s42250-020-00206-8","volume":"4","author":"Umar H.I.","year":"2021","unstructured":"Umar H.I.; Awonyemi I.O.; Abegunde S.M.; Igbe F.O.; Siraj B.; In silico molecular docking of bioactive molecules isolated from Raphia taedigera seed oil as potential anti-cancer agents targeting vascular endothelial growth factor receptor-2. Chemistry Africa 2021,4(1),161-174","journal-title":"Chemistry Africa"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4062\/biomolther.2020.205","volume":"29","author":"Lin C.L.","year":"2021","unstructured":"Lin C.L.; Tsai M.L.; Chen Y.; Platelet-derived growth factor receptor-\u03b1 subunit targeting suppresses metastasis in advanced thyroid cancer in vitro and in vivo. Biomol Ther 2021,29(5),551-561","journal-title":"Biomol Ther"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fcell.2017.00101","volume":"5","author":"Comunanza V.","year":"2017","unstructured":"Comunanza V.; Bussolino F.; Therapy for cancer: Strategy of combining anti-angiogenic and target therapies. Front Cell Dev Biol 2017,5(101),101","journal-title":"Front Cell Dev Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cells8091102","volume":"8","author":"J\u00e1szai J.","year":"2019","unstructured":"J\u00e1szai J.; Schmidt M.; Trends and challenges in tumor anti-angiogenic therapies. Cells 2019,8(9),1102","journal-title":"Cells"},{"key":"ref=40","first-page":"D271","volume":"45","author":"Rose P.","year":"2016","unstructured":"Rose P.; Prli\u0107 A.; Altunkaya A.; The RCSB protein data bank: Integrative view of protein, gene and 3D structural information. Nucleic Acids Res 2016,45(D1),D271-D281","journal-title":"Nucleic Acids Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"Wishart D.S.","year":"2006","unstructured":"Wishart D.S.; Knox C.; Guo A.C.; DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006,34(90001(S1)),D668-D672","journal-title":"Nucleic Acids Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","volume":"44","author":"Kim S.","year":"2016","unstructured":"Kim S.; Thiessen P.A.; Bolton E.E.; PubChem substance and compound databases. Nucleic Acids Res 2016,44(D1),D1202-D1213","journal-title":"Nucleic Acids Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/bioinformatics\/bty707","volume":"35","author":"Yang H.","year":"2019","unstructured":"Yang H.; Lou C.; Sun L.; admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics 2019,35(6),1067-1069","journal-title":"Bioinformatics"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O.; Olson A.J.; AutoDock vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010,31(2),455-461","journal-title":"J Comput Chem"},{"key":"ref=45","first-page":"55","volume":"60","author":"Ranade P.B.","year":"2023","unstructured":"Ranade P.B.; Navale D.N.; Zote S.W.; Kulal D.K.; Wagh S.J.; Blind docking of 4-Amino-7-Chloroquinoline analogs as potential dengue virus protease inhibitor using CB Dock a web server. Indian J Biochem Biophys 2023,60(1),55-57","journal-title":"Indian J Biochem Biophys"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/wsbm.1337","volume":"8","author":"Hodos R.A.","year":"2016","unstructured":"Hodos R.A.; Kidd B.A.; Shameer K.; Readhead B.P.; Dudley J.T.; In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 2016,8(3),186-210","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.drudis.2017.10.009","volume":"23","author":"Delavan B.","year":"2018","unstructured":"Delavan B.; Roberts R.; Huang R.; Bao W.; Tong W.; Liu Z.; Computational drug repositioning for rare diseases in the era of precision medicine. Drug Discov Today 2018,23(2),382-394","journal-title":"Drug Discov Today"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","volume":"15","author":"Talevi A.","year":"2020","unstructured":"Talevi A.; Bellera C.L.; Challenges and opportunities with drug repurposing: Finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov 2020,15(4),397-401","journal-title":"Expert Opin Drug Discov"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4103\/0022-3859.81870","volume":"57","author":"Padhy B.M.","year":"2011","unstructured":"Padhy B.M.; Gupta Y.K.; Drug repositioning: Re-investigating existing drugs for new therapeutic indications. J Postgrad Med 2011,57(2),153-160","journal-title":"J Postgrad Med"},{"key":"ref=50","author":"Rudrapal M.","year":"2020","unstructured":"Rudrapal M.; Khairnar S.J.; Jadhav A.G.;  Drug repurposing (DR): An emerging approach in drug discovery 2020","journal-title":"Drug repurposing (DR): An emerging approach in drug discovery"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bph.13798","volume":"175","author":"Cha Y.","year":"2018","unstructured":"Cha Y.; Erez T.; Reynolds I.J.; Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol 2018,175(2),168-180","journal-title":"Br J Pharmacol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","volume":"42","author":"Roessler H.I.","year":"2021","unstructured":"Roessler H.I.; Knoers N.V.A.M.; van Haelst M.M.; van Haaften G.; Drug repurposing for rare diseases. Trends Pharmacol Sci 2021,42(4),255-267","journal-title":"Trends Pharmacol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"Pushpakom S.","year":"2019","unstructured":"Pushpakom S.; Iorio F.; Eyers P.A.; Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 2019,18(1),41-58","journal-title":"Nat Rev Drug Discov"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e13009","DOI":"10.1111\/cpr.13009","volume":"54","author":"Liu G.","year":"2021","unstructured":"Liu G.; Chen T.; Ding Z.; Wang Y.; Wei Y.; Wei X.; Inhibition of FGF\u2010FGFR and VEGF\u2010VEGFR signalling in cancer treatment. Cell Prolif 2021,54(4),e13009","journal-title":"Cell Prolif"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","volume":"120","author":"Roskoski R.","year":"2017","unstructured":"Roskoski R.; Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol Res 2017,120,116-132","journal-title":"Pharmacol Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/BCR.0b013e3181c7ed82","volume":"31","author":"Ucuzian A.A.","year":"2010","unstructured":"Ucuzian A.A.; Gassman A.A.; East A.T.; Greisler H.P.; Molecular mediators of angiogenesis. J Burn Care Res 2010,31(1),158-175","journal-title":"J Burn Care Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"153956","DOI":"10.1016\/j.prp.2022.153956","volume":"236","author":"Ruan L.","year":"2022","unstructured":"Ruan L.; Zhang S.; Chen X.; Liang W.; Xie Q.; Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential. Pathol Res Pract 2022,236,153956","journal-title":"Pathol Res Pract"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.3390\/ijms23136934","volume":"23","author":"Qi S.","year":"2022","unstructured":"Qi S.; Deng S.; Lian Z.; Yu K.; Novel drugs with high efficacy against tumor angiogenesis. Int J Mol Sci 2022,23(13),6934","journal-title":"Int J Mol Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"10053","DOI":"10.1007\/s13277-016-5069-z","volume":"37","author":"Appiah-Kubi K.","year":"2016","unstructured":"Appiah-Kubi K.; Wang Y.; Qian H.; Platelet-derived growth factor receptor\/platelet-derived growth factor (PDGFR\/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers. Tumour Biol 2016,37(8),10053-10066","journal-title":"Tumour Biol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/joim.12690","volume":"283","author":"Heldin C.H.","year":"2018","unstructured":"Heldin C.H.; Lennartsson J.; Westermark B.; Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. J Intern Med 2018,283(1),16-44","journal-title":"J Intern Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbrc.2016.08.035","volume":"478","author":"Zhang H.","year":"2016","unstructured":"Zhang H.; Sun J.D.; Yan L.; Zhao X.P.; PDGF-D\/PDGFR\u03b2 promotes tongue squamous carcinoma cell (TSCC) progression via activating p38\/AKT\/ERK\/EMT signal pathway. Biochem Biophys Res Commun 2016,478(2),845-851","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.3390\/ijms21072360","volume":"21","author":"Lin L.H.","year":"2020","unstructured":"Lin L.H.; Lin J.S.; Yang C.C.; Cheng H.W.; Chang K.W.; Liu C.J.; Overexpression of platelet-derived growth factor and its receptor are correlated with oral tumorigenesis and poor prognosis in oral squamous cell carcinoma. Int J Mol Sci 2020,21(7),2360","journal-title":"Int J Mol Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cytogfr.2014.03.003","volume":"25","author":"Demoulin J.B.","year":"2014","unstructured":"Demoulin J.B.; Essaghir A.; PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev 2014,25(3),273-283","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1021\/ci5004027","volume":"54","author":"Mikulskis P.","year":"2014","unstructured":"Mikulskis P.; Genheden S.; Ryde U.; A large-scale test of free-energy simulation estimates of protein-ligand binding affinities. J Chem Inf Model 2014,54(10),2794-2806","journal-title":"J Chem Inf Model"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"20200007","DOI":"10.1098\/rsfs.2020.0007","volume":"10","author":"Wan S.","year":"2020","unstructured":"Wan S.; Bhati A.P.; Zasada S.J.; Coveney P.V.; Rapid, accurate, precise and reproducible ligand\u2013protein binding free energy prediction. Interface Focus 2020,10(6),20200007","journal-title":"Interface Focus"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"772418","DOI":"10.3389\/fphar.2021.772418","volume":"12","author":"Mitra S.","year":"2022","unstructured":"Mitra S.; Anand U.; Jha N.K.; Anticancer applications and pharmacological properties of piperidine and piperine: A comprehensive review on molecular mechanisms and therapeutic perspectives. Front Pharmacol 2022,12(772418),772418","journal-title":"Front Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2017.01.042","volume":"393","author":"Dilly S.J.","year":"2017","unstructured":"Dilly S.J.; Clark A.J.; Marsh A.; A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment. Cancer Lett 2017,393(16-21),16-21","journal-title":"Cancer Lett"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/aps.2012.76","volume":"33","author":"Mao W.","year":"2012","unstructured":"Mao W.; Shao M.; Gao P.; The important roles of RET, VEGFR2 and the RAF\/MEK\/ERK pathway in cancer treatment with sorafenib. Acta Pharmacol Sin 2012,33(10),1311-1318","journal-title":"Acta Pharmacol Sin"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12013-013-9781-7","volume":"69","author":"Mei J.","year":"2014","unstructured":"Mei J.; Zhu X.; Wang Z.; Wang Z.; VEGFR, RET, and RAF\/MEK\/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment. Cell Biochem Biophys 2014,69(1),151-156","journal-title":"Cell Biochem Biophys"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"Apte R.S.","year":"2019","unstructured":"Apte R.S.; Chen D.S.; Ferrara N.; VEGF in signaling and disease: Beyond discovery and development. Cell 2019,176(6),1248-1264","journal-title":"Cell"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"e28222","DOI":"10.1002\/pbc.28222","volume":"67","author":"Harrison D.J.","year":"2020","unstructured":"Harrison D.J.; Gill J.D.; Roth M.E.; Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatr Blood Cancer 2020,67(6),e28222","journal-title":"Pediatr Blood Cancer"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/jcm8060900","volume":"8","author":"Pan P.J.","year":"2019","unstructured":"Pan P.J.; Liu Y.C.; Hsu F.T.; Protein kinase B and extracellular signal-regulated kinase inactivation is associated with regorafenib-induced inhibition of osteosarcoma progression in vitro and in vivo. J Clin Med 2019,8(6),900","journal-title":"J Clin Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1039\/C7MD00449D","volume":"8","author":"Rakesh K.P.","year":"2017","unstructured":"Rakesh K.P.; Shantharam C.S.; Sridhara M.B.; Manukumar H.M.; Qin H.L.; Benzisoxazole: A privileged scaffold for medicinal chemistry. MedChemComm 2017,8(11),2023-2039","journal-title":"MedChemComm"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1517\/13543776.2015.1027192","volume":"25","author":"Uto Y.","year":"2015","unstructured":"Uto Y.; 1,2-Benzisoxazole compounds: A patent review (2009 \u2013 2014). Expert Opin Ther Pat 2015,25(6),643-662","journal-title":"Expert Opin Ther Pat"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s43094-021-00335-y","volume":"7","author":"Abdelshaheed M.M.","year":"2021","unstructured":"Abdelshaheed M.M.; Fawzy I.M.; El-Subbagh H.I.; Youssef K.M.; Piperidine nucleus in the field of drug discovery. Future J Pharmaceut Sci 2021,7(1),188","journal-title":"Future J Pharmaceut Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ejmech.2018.08.017","volume":"157","author":"Goel P.","year":"2018","unstructured":"Goel P.; Alam O.; Naim M.J.; Nawaz F.; Iqbal M.; Alam M.I.; Recent advancement of piperidine moiety in treatment of cancer- A review. Eur J Med Chem 2018,157,480-502","journal-title":"Eur J Med Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"8232","DOI":"10.3390\/ijms21218232","volume":"21","author":"Keretsu S.","year":"2020","unstructured":"Keretsu S.; Ghosh S.; Cho S.J.; Molecular modeling study of c-KIT\/PDGFR\u03b1 dual inhibitors for the treatment of gastrointestinal stromal tumors. Int J Mol Sci 2020,21(21),8232","journal-title":"Int J Mol Sci"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1060012","DOI":"10.3389\/fnins.2022.1060012","volume":"16","author":"Yang W.","year":"2022","unstructured":"Yang W.; Wang S.; Zhang X.; New natural compound inhibitors of PDGFRA (platelet-derived growth factor receptor \u03b1) based on computational study for high\u2212 grade glioma therapy. Front Neurosci 2022,16,1060012","journal-title":"Front Neurosci"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.2174\/0929867323666160411142532","volume":"23","author":"Garuti L.","year":"2016","unstructured":"Garuti L.; Roberti M.; Bottegoni G.; Ferraro M.; Diaryl urea: A privileged structure in anticancer agents. Curr Med Chem 2016,23(15),1528-1548","journal-title":"Curr Med Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/jphp.12440","volume":"67","author":"Lu Y.Y.","year":"2015","unstructured":"Lu Y.Y.; Wang J.J.; Zhang X.K.; Li W.B.; Guo X.L.; 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt\/\u03b2-catenin pathway and receptor tyrosine kinases. J Pharm Pharmacol 2015,67(10),1393-1405","journal-title":"J Pharm Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/app11010374","volume":"11","author":"Catalano A.","year":"2021","unstructured":"Catalano A.; Iacopetta D.; Sinicropi M.S.; Franchini C.; Diarylureas as antitumor agents. Appl Sci 2021,11(1),374","journal-title":"Appl Sci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.2174\/0929867329666220111121251","volume":"29","author":"Catalano A.","year":"2022","unstructured":"Catalano A.; Diarylurea: A privileged scaffold in drug discovery and therapeutic development. Curr Med Chem 2022,29(25),4302-4306","journal-title":"Curr Med Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.bmc.2015.12.038","volume":"24","author":"Shan Y.","year":"2016","unstructured":"Shan Y.; Wang C.; Zhang L.; Wang J.; Wang M.; Dong Y.; Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors. Bioorg Med Chem 2016,24(4),750-758","journal-title":"Bioorg Med Chem"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.medidd.2019.100009","volume":"2","author":"Modi S.","year":"2019","unstructured":"Modi S.; Kulkarni V.M.; Vascular endothelial growth factor receptor (VEGFR-2)\/KDR inhibitors: Medicinal chemistry perspective. Med Drug Discov 2019,2,100009","journal-title":"Med Drug Discov"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570163820666230606113158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/217693\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570163820666230606113158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T11:49:04Z","timestamp":1699616944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/217693\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163820666230606113158","relation":{},"ISSN":["1570-1638"],"issn-type":[{"value":"1570-1638","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e060623217693"}}